Related Experiment Video
Updated: Aug 18, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
20th-century advances in drug therapy in oncology--Part. II
J P Dutcher1, Y Novik, K O'Boyle
1Our Lady of Mercy Cancer Center, New York Medical College, Bronx 10466, USA.
Abstract:
Ongoing research in cancer therapy has led to the development of antineoplastic agents which target specific components of the cell cycle. In Part II of this series, we discuss agents which target the mitotic mechanism by inhibiting microtubules. Although many of these agents are being shown to have multiple effects, the Vinca alkaloids and the taxanes are known as antimitotic drugs. They are among the most important anticancer agents currently available, and because of their unique mechanisms, can be combined with a wide variety of other antineoplastic agents in a spectrum of diseases. In addition, in part II, we are discussing agents that target DNA and prevent replication and thus cell growth by inhibiting the enzymes which protect DNA during replication, the topoisomerases. These drugs, too, have unique mechanisms of action and have become major components of combination regimens. The topoisomerase I inhibitors are new drugs derived from an older parent drug, and their full possibilities are still being explored.
Insights
This study reviews antimitotic drugs like Vinca alkaloids and taxanes that inhibit microtubules, and topoisomerase inhibitors that prevent DNA replication in cancer therapy. These agents are crucial for combination cancer treatments.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Cancer therapy research focuses on cell cycle-specific antineoplastic agents.
- Antimitotic drugs targeting microtubules, such as Vinca alkaloids and taxanes, are vital in cancer treatment.
- DNA replication inhibitors, including topoisomerase inhibitors, are also key components of combination cancer regimens.
Purpose of the Study:
- To discuss antineoplastic agents that target the cell cycle, specifically microtubule inhibitors and DNA replication inhibitors.
- To highlight the mechanisms of action and clinical significance of Vinca alkaloids, taxanes, and topoisomerase inhibitors.
- To explore the potential of these agents in combination cancer therapy.
Main Methods:
- Review of existing literature on antimitotic drugs and topoisomerase inhibitors.
- Analysis of the mechanisms by which these agents affect cell cycle and DNA replication.
- Discussion of their roles in current cancer treatment strategies and combination regimens.
Main Results:
- Vinca alkaloids and taxanes are effective antimitotic drugs inhibiting microtubules.
- Topoisomerase inhibitors target DNA replication and cell growth by inhibiting key enzymes.
- Both drug classes possess unique mechanisms, making them valuable in combination therapies for various cancers.
Conclusions:
- Antimitotic agents and topoisomerase inhibitors are essential in modern cancer therapy.
- Their distinct mechanisms facilitate combination regimens across a spectrum of diseases.
- Further research into topoisomerase I inhibitors is ongoing to explore their full therapeutic potential.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...